The <i>FGFR3</i> Mutation is Related to Favorable pT1 Bladder CancerBas W.G. van Rhijn, Bharati Bapat, Theodorus van der Kwast et al.|The Journal of Urology|2011Cited by 102
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)Devaki Shilpa Surasi, Morand Piert, Phillip Davis et al.|European Urology|2023Cited by 90
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†Bas W.G. van Rhijn, Tahlita C.M. Zuiverloon, Laura S. Mertens et al.|European Urology|2020Cited by 89
Diagnostic Performance and Safety of <sup>18</sup> F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)Ashesh B. Jani, Katherine Zukotynski, Gregory Ravizzini et al.|The Journal of Urology|2023Cited by 65
Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancerBas W.G. van Rhijn, Alexandre R. Zlotta, Liyang Liu et al.|British Journal of Urology|2012Cited by 64